

Financial news for IMDZ dated on 2019-04-01: Biotech Winners, Losers In Q1

Financial news for IMDZ dated on 2019-03-25: These Are Some Of The Best-Performing Leveraged ETFs Of The Year

Financial news for IMDZ dated on 2019-03-05: Merck Begins Tender Offer To Acquire Immune Design

Financial news for IMDZ dated on 2019-02-25: Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired

Financial news for IMDZ dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for IMDZ dated on 2019-02-22: 8 Biggest Price Target Changes For Friday

Financial news for IMDZ dated on 2019-02-22: The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Financial news for IMDZ dated on 2019-02-22: RBC Capital Downgrades Immune Design to Sector Perform, Lowers Price Target to \$6

Financial news for IMDZ dated on 2019-02-22: 65 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2019-02-21: Mid-Afternoon Market Update: Dow Falls 150 Points; Delphi Technologies Shares Spike Higher

Financial news for IMDZ dated on 2019-02-21: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMDZ dated on 2019-02-21: Mid-Day Market Update: Immune Design Jumps Following Acquisition News; Carbon Black Shares Slide

Financial news for IMDZ dated on 2019-02-21: Mid-Morning Market Update: Markets Open Lower; Domino's Pizza Misses Q4 Views

Financial news for IMDZ dated on 2019-02-21: Merck To Buy Immune Design For \$300M

Financial news for IMDZ dated on 2019-02-21: Immune Design shares are trading higher after Merck announced it would acquire the company for \$5.85 per share cash.

Financial news for IMDZ dated on 2019-02-21: 31 Stocks Moving In Thursday's Pre-Market Session

Financial news for IMDZ dated on 2019-02-21: Merck To Acquire Immune Design At \$5.85/Share In Cash, Or ~\$300M

Financial news for IMDZ dated on 2018-12-21: The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Financial news for IMDZ dated on 2018-12-10: Immune Design Says On Dec 6, Received Notice From Sanofi US Services, That It Elected To Terminate License Agreement Dated As Of August 6, 2014

Financial news for IMDZ dated on 2018-12-02: Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab at ASH 2018

Financial news for IMDZ dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for IMDZ dated on 2018-11-21: Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Financial news for IMDZ dated on 2018-11-06: Immune Design Q3 EPS \$(0.29) Beats \$(0.32) Estimate, Sales \$462K Miss \$1.1M Estimate

Financial news for IMDZ dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for IMDZ dated on 2018-10-30: Stocks Which Set New 52-Week Low Yesterday, October 29th

Financial news for IMDZ dated on 2018-10-30: The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assentio

Financial news for IMDZ dated on 2018-10-29: Stocks Which Set New 52-Week Low Friday, October 26th

Financial news for IMDZ dated on 2018-10-15: 44 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2018-10-14: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for IMDZ dated on 2018-10-12: Mid-Afternoon Market Update: Corium Surges On Acquisition News; Immune Design Shares Slide

Financial news for IMDZ dated on 2018-10-12: 41 Stocks Moving In Friday's Mid-Day Session

Financial news for IMDZ dated on 2018-10-12: Mid-Day Market Update: EXFO Falls After Q4 Results; Iovance Biotherapeutics Shares Climb

Financial news for IMDZ dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for IMDZ dated on 2018-10-12: Mid-Morning Market Update: Markets Open Higher; JPMorgan Earnings Top Estimates

Financial news for IMDZ dated on 2018-10-12: Immune Design shares are trading lower after the company said it will discontinue its SYNOVATE trial.

Financial news for IMDZ dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for IMDZ dated on 2018-10-11: Immune Design To Focus On Accelerating And Expanding Development Of G100 For Lymphoma; CMB305 Cancer Vaccine To Be Deprioritized

Financial news for IMDZ dated on 2018-08-29: 34 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMDZ dated on 2018-08-29: Benzinga's Top Upgrades, Downgrades For August 29, 2018

Financial news for IMDZ dated on 2018-08-29: H.C. Wainwright Initiates Coverage On Immune Design with Buy Rating, Announces \$11 Price Target

Financial news for IMDZ dated on 2018-08-01: Immune Design Q2 EPS \$(0.29) Beats \$(0.30) Estimate, Sales \$755K Miss \$1.29M Estimate

Financial news for IMDZ dated on 2018-06-25: Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies

Financial news for IMDZ dated on 2018-05-24: Immune Design Announces Start of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma

Financial news for IMDZ dated on 2018-05-02: Immune Design Corp Q1 EPS \$(0.28) Beats \$(0.29) Est., Sales \$0.5M Misses \$1.8M Est.

Financial news for IMDZ dated on 2018-03-14: Immune Design Reports Q4 EPS \$(0.29) vs \$(0.38) Est., Sales \$485K vs \$1.03M Est.

Financial news for IMDZ dated on 2018-03-12: Immune Design Corp Shares Up 8.8% After Co. Reported Its CMB305 Has Been Well Tolerated

Financial news for IMDZ dated on 2018-03-12: Immune Design Says its CMB305 Has Been Well Tolerated, Median Survival is 23.7 Months

Financial news for IMDZ dated on 2018-03-09: 56 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2017-12-10: Immune Design Reports Combination of G100 with KEYTRUDA Triggers Robust Systemic Responses in Follicular NHL Patients at #ASH2017

Financial news for IMDZ dated on 2017-11-14: 34 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2017-11-13: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for IMDZ dated on 2017-11-06: EcoR1 Reports 7.4% Stake In Immune Design

Financial news for IMDZ dated on 2017-11-02: Immune Design Shares Up 7% Just After Open Following Mixed Q3 Earnings; 1 Day Before Report, Director Lewis Coleman

Purchased 65K Shares

Financial news for IMDZ dated on 2017-11-01: Immune Design Q3 EPS \$(0.52) vs \$(0.63) Est., Sales \$516K vs \$1.36M Est.

Financial news for IMDZ dated on 2017-11-01: Immune Design Director Lewis Coleman Buys 65,000 @ Avg Price: \$4.07 -Form4

Financial news for IMDZ dated on 2017-10-27: Immune Design To Report Q3 Earnings On Wed., Nov. 1 After Market Close

Financial news for IMDZ dated on 2017-10-25: 40 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2017-10-25: Immune Design Prices 19.5M Share Public Offering of Common Stock @\$4.10/Share

Financial news for IMDZ dated on 2017-10-24: Mid-Afternoon Market Update: Crude Oil Up Over 1%; Polaris Shares Surge On Upbeat Earnings

Financial news for IMDZ dated on 2017-10-24: 33 Stocks Moving In Tuesday's Mid-Day Session

Financial news for IMDZ dated on 2017-10-24: Mid-Day Market Update: Dow Rises 175 Points; Identiv Shares Plunge

Financial news for IMDZ dated on 2017-10-24: Mid-Morning Market Update: Markets Open Higher; General Motors Profit Tops Expectations

Financial news for IMDZ dated on 2017-10-24: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IMDZ dated on 2017-10-23: Immune Design Reports 16M Share Common Stock Offering

Financial news for IMDZ dated on 2017-10-20: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for IMDZ dated on 2017-10-19: Immune Design Press Release Confirms Receipt Of Orphan Drug Designation From The EMA For G100

Financial news for IMDZ dated on 2017-10-19: Immune Design Shares Volatile As Traders Circulate EC Public Health Doc Showing Orphan Medicinal Product Designation For Co.'s Follicular Lymphoma Treatment

Financial news for IMDZ dated on 2017-10-19: 38 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2017-10-18: 32 Stocks Moving In Wednesday's Mid-Day Session

Financial news for IMDZ dated on 2017-10-18: 32 Biggest Movers From Yesterday

Financial news for IMDZ dated on 2017-10-17: Mid-Afternoon Market Update: Badger Meter Falls On Downbeat Q3 Results; Diffusion Pharmaceuticals Shares Climb

Financial news for IMDZ dated on 2017-10-17: Immune Design Shares Spiking Higher Away From Session Lows As Hearing RBC Raised Price Target To New Street High Of \$23

Financial news for IMDZ dated on 2017-10-17: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for IMDZ dated on 2017-10-17: Immune Design Shares Down 17% Tues., Down 26% Since Mon. After-Hours High; Co. Announced FDA Feedback Related To Its Phase 3 Trial Design For CMB305; Was Also Downgraded To Market Perform By Wells Fargo

Financial news for IMDZ dated on 2017-10-17: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for IMDZ dated on 2017-10-16: Immune Design Announces FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

Financial news for IMDZ dated on 2017-09-15: 15 Biggest Mid-Day Losers For Friday

Financial news for IMDZ dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for IMDZ dated on 2017-09-08: Immune Design Announces New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

Financial news for IMDZ dated on 2017-08-31: Immune Design Announces Positive New CMB305 + Checkpoint Inhibitor Topline Data

Financial news for IMDZ dated on 2017-08-02: Immune Design Reports Q2 EPS \$(0.54) vs \$(0.63) Est., Sales \$729K vs \$1.79M Est.

Financial news for IMDZ dated on 2017-06-22: 11 Biggest Mid-Day Losers For Thursday

Financial news for IMDZ dated on 2017-05-17: UPDATE: Immune Design Reports New Data That 'Validate' Co's Lead Programs And Discovery Platforms

Financial news for IMDZ dated on 2017-05-17: Immune Design Says Data from CMB305, G100 Showed 'survival data meaningfully exceed published survival outcomes for standard of care therapy in comparable STS patients with recurrent metastatic disease'

Financial news for IMDZ dated on 2017-05-17: Immune Design Reports Q1 EPS \$(0.50) vs \$(0.62) Est., Sales \$5.465M vs \$1.53M Est.

Financial news for IMDZ dated on 2017-05-17: Earnings Scheduled For May 17, 2017

Financial news for IMDZ dated on 2017-03-09: Recent Strength In Immune Design Being Attributed To Takeover Chatter

Financial news for IMDZ dated on 2017-02-22: Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate.

Financial news for IMDZ dated on 2016-10-04: Immune Design Names Dr. Sergey Yurasov Chief Medical Officer

Financial news for IMDZ dated on 2016-09-15: 15 Biggest Mid-Day Losers For Thursday

Financial news for IMDZ dated on 2016-09-15: Stocks Hitting 52-Week Lows

Financial news for IMDZ dated on 2016-09-14: Immune Design Announces Proposed Public Offering of Common Stock

Financial news for IMDZ dated on 2016-08-09: Immune Design Corp. Reports Q2 EPS \$(0.71) vs. Est. \$(0.61), Rev. \$1.13M vs. Est. \$1.85M

Financial news for IMDZ dated on 2016-07-14: Stocks Hitting 52-Week Lows

Financial news for IMDZ dated on 2016-05-10: Immune Design Reports Q1 EPS \$(0.61) vs. Est. \$(0.62)

Financial news for IMDZ dated on 2016-05-09: Immune Design, Gritstone Oncology Report Clinical Collaboration for Neoantigen Cancer Immunotherapy

Financial news for IMDZ dated on 2016-03-10: Immune Design Reports Q4 EPS \$(0.60) vs \$(0.54) Est., Sales \$1.1M vs \$1.06M Est.

Financial news for IMDZ dated on 2016-02-09: Immune Design Announces Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-oncology Product Candidates

Financial news for IMDZ dated on 2016-01-28: FDA Approves First Drug To Produce Evidence Of Survival Benefits in Lipsarcoma

Financial news for IMDZ dated on 2016-01-08: Immune Design Receives U.S. FDA Orphan Drug Designation For Comp. Components Of CMB305

Financial news for IMDZ dated on 2015-12-30: 8-K from Immune Design Shows Co. Entered Second Amended, Restated License Deal with Infectious Disease Research Institute

Financial news for IMDZ dated on 2015-11-12: Immune Design Reports Q3 EPS \$(0.37) vs \$(0.39) Est., Sales 4.7M vs \$4.1M Est.

Financial news for IMDZ dated on 2015-11-03: Immune Design Presents Preclinical Data on G100 and ZVex(TM) in Combination With Check Point Inhibitors at the 2015 Society for Immunotherapy of Cancer Annual Meeting

Financial news for IMDZ dated on 2015-10-29: MEDI7510 for Respiratory Syncytial Virus Advances to Phase 2 Leverages Immune Design's GLAAS(TM) Discovery Platform

Financial news for IMDZ dated on 2015-09-09: Biotech Investors Still Have Opportunity

Financial news for IMDZ dated on 2015-08-12: Immune Design Reports Q2 EPS \$(0.54) vs. Est. \$(0.47)

Financial news for IMDZ dated on 2015-08-12: Immune Design Reports Phase 2 Cancer

Immunotherapy Trial Partnership

Financial news for IMDZ dated on 2015-05-19: 7 Biotech Stocks Moving Off The UBS Healthcare Conference

Financial news for IMDZ dated on 2015-05-14: Immune Design Reports Q1 Loss \$0.56 Vs Est Loss \$0.64, Sales \$1.94M vs Est \$1.30M

Financial news for IMDZ dated on 2015-04-15: Immune Design Prices 3M Shares at \$26.50/Share

Financial news for IMDZ dated on 2015-04-15: Amended S-1 from Immune Design Shows Increase in Offering from \$60M to \$75M

Financial news for IMDZ dated on 2015-04-06: Immune Design Files for Up to \$60M Common Stock Offering

Financial news for IMDZ dated on 2015-04-01: Morning Market Gainers

Financial news for IMDZ dated on 2015-04-01: Jefferies Upgrades Immune Design to Buy, Lowers PT to \$29.00

Financial news for IMDZ dated on 2015-03-31: Immune Design Reports Positive Topline Data From Three Phase 1 Clinical Trials of Immuno-Oncology Agents

Financial news for IMDZ dated on 2015-03-31: Immune Design Reports Q4 EPS -\$0.78 Vs Est -\$0.65, Sales \$1.8M Vs Est \$750K

Financial news for IMDZ dated on 2015-03-26: Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent

Financial news for IMDZ dated on 2015-03-11: 18 Biotech Stocks These Wall Street Analysts Are Tracking

Financial news for IMDZ dated on 2015-02-11: Immune Design Announces First Patients Dosed in Phase 1 Clinical Trial of G100

Financial news for IMDZ dated on 2015-01-12: Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014

Financial news for IMDZ dated on 2015-01-08: TubeMogul And Immune Design: 2 Big IPO Winners

Financial news for IMDZ dated on 2014-12-30: Morning Market Losers

Financial news for IMDZ dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for IMDZ dated on 2014-08-18: Jefferies Initiates Coverage on Immune Design Corp at Buy, Announces \$15.00 PT

Financial news for IMDZ dated on 2014-08-18: Wells Fargo Initiates Coverage on Immune Design Corp at Outperform

Financial news for IMDZ dated on 2014-08-05: Topspin Fund Reports 5.6% Passive Stake in Immune Design Corp as of July 26

Financial news for IMDZ dated on 2014-07-31: Amended 13D Filing from ProQuest on Immune Design Shows 17.1% Stake

Financial news for IMDZ dated on 2014-07-25: IMDZ Announces Filing Of New Lawsuit By Theravectys SA

Financial news for IMDZ dated on 2014-07-24: IPO for Immune Design Opens at \$12.15/Share, Priced at \$12

Financial news for IMDZ dated on 2014-07-24: Immune Design Prices 5M Share IPO at \$12.00/Share

Financial news for IMDZ dated on 2014-07-21: IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?

Financial news for IMDZ dated on 2014-07-14: Immune Design Expects 4.65M Share IPO to Price \$12.00-\$14.00/Share